StockData
Avalo Therapeutics, Inc. logo

Avalo Therapeutics, Inc. (AVTX) stock

AVTXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 8/30
$6.70−0.43 (-6.03%)

Close on Nov 18, 2026Market cap $359.32MP/E –Yield –

Avalo Therapeutics operating income

Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.

Avalo Therapeutics's operating income for the twelve months ending Jun 30, 2026 was -$91.36M. For fiscal 2025 it was -$72.93M. The highest annual figure on record is $13.89M in fiscal 2017.

Annual operating income

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$72.93M–
FY2024Dec 31, 2024-$68.51M–
FY2023Dec 31, 2023-$27.35M–
FY2022Dec 31, 2022-$37.44M–
FY2021Dec 31, 2021-$82.13M–
FY2020Dec 31, 2020-$72.84M–
FY2019Dec 31, 2019-$16.14M–
FY2018Dec 31, 2018-$35.38M-354.7%
FY2017Dec 31, 2017$13.89M–
FY2016Dec 31, 2016-$16.08M–
FY2015Dec 31, 2015-$11.01M–
FY2014Dec 31, 2014-$17.12M–
FY2013Dec 31, 2013-$12.93M–

Quarterly operating income

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$31.52M–
Q1 FY2026Mar 31, 2026-$20.90M–
Q4 FY2025Dec 31, 2025-$19.74M–
Q3 FY2025Sep 30, 2025-$19.20M–
Q2 FY2025Jun 30, 2025-$19.32M–
Q1 FY2025Mar 31, 2025-$14.67M–
Q4 FY2024Dec 31, 2024-$13.31M–
Q3 FY2024Sep 30, 2024-$12.86M–
Q2 FY2024Jun 30, 2024-$9.58M–
Q1 FY2024Mar 31, 2024-$32.77M–
Q4 FY2023Dec 31, 2023-$7.66M–
Q3 FY2023Sep 30, 2023-$3.75M-191.6%
Q2 FY2023Jun 30, 2023-$7.15M–
Q1 FY2023Mar 31, 2023-$8.79M–
Q4 FY2022Dec 31, 2022-$8.86M–
Q3 FY2022Sep 30, 2022$4.10M–
Q2 FY2022Jun 30, 2022-$11.83M–
Q1 FY2022Mar 31, 2022-$20.85M–
Q4 FY2021Dec 31, 2021-$17.96M–
Q3 FY2021Sep 30, 2021-$16.46M–
Q2 FY2021Jun 30, 2021-$17.13M–
Q1 FY2021Mar 31, 2021-$30.58M–
Q4 FY2020Dec 31, 2020-$16.34M–
Q3 FY2020Sep 30, 2020-$13.28M–
Q2 FY2020Jun 30, 2020-$11.82M–
Q1 FY2020Mar 31, 2020-$31.41M–
Q4 FY2019Dec 31, 2019-$5.72M–
Q3 FY2019Sep 30, 2019-$2.86M–
Q2 FY2019Jun 30, 2019-$2.55M–
Q1 FY2019Mar 31, 2019-$5.00M–
Q4 FY2018Dec 31, 2018-$1.56M–
Q3 FY2018Sep 30, 2018-$24.31M-210.9%
Q2 FY2018Jun 30, 2018-$5.75M–
Q1 FY2018Mar 31, 2018-$3.75M–
Q4 FY2017Dec 31, 2017-$4.36M–
Q3 FY2017Sep 30, 2017$21.92M–
Q2 FY2017Jun 30, 2017-$1.77M–
Q1 FY2017Mar 31, 2017-$1.90M–
Q4 FY2016Dec 31, 2016-$1.69M–
Q3 FY2016Sep 30, 2016-$5.96M–

More Avalo Therapeutics figures

See a number that looks wrong?